Sep 30 |
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
|
Sep 23 |
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
|
Sep 10 |
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
|
Sep 9 |
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
|
Aug 29 |
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
|
Aug 27 |
Rallybio to Present at Upcoming Investor Conferences
|
Aug 14 |
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
|
Aug 10 |
Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?
|
Aug 9 |
Rallybio GAAP EPS of -$0.67 misses by $0.30, revenue of $0.3M
|
Aug 8 |
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
|